FDA De Novo Classification Strategy

The analysis confirmed that no legally marketed predicate could support a scientifically defensible claim of substantial equivalence.

Why the De Novo Pathway Was Appropriate

The conclusion that no suitable predicate existed did not represent a setback. Instead, it created an opportunity.

The FDA’s De Novo pathway was specifically established for novel devices that present low to moderate risk but lack an appropriate predicate. Successful De Novo classification not only authorizes marketing of the new device but also establishes a new device classification that may serve as a predicate for future technologies.

E&E Medicals explained to executive leadership that the De Novo pathway would allow the company to present the product on its own scientific merits rather than attempting to compare it to technologies that were fundamentally different.

This strategic shift also aligned with the company’s long-term business objectives by positioning it as an innovator capable of defining a new category within digital health.

Establishing the Regulatory Vision

Once the De Novo pathway had been selected, E&E Medicals worked with company leadership to establish a long-term regulatory vision extending beyond initial authorization.

The objective was not simply to obtain FDA marketing authorization but to build a regulatory framework capable of supporting future software updates, expanded indications, international market access, and continued product evolution.

A Regulatory Master Plan was developed that integrated:

· Software development milestones

· Clinical evidence generation